Recombinant human erythropoietin treatment for chemotherapy-related anemia in children
PEDIATRICS, cilt.103, sa.2, 1999 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 103 Sayı: 2
- Basım Tarihi: 1999
- Doi Numarası: 10.1542/peds.103.2.e16
- Dergi Adı: PEDIATRICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Hacettepe Üniversitesi Adresli: Evet
Özet
Objective. The efficacy and safety of recombinant human erythropoietin (rHuEPO) treatment in chemotherapy-induced anemia in children were investigated, rHuEPO is used to treat chemotherapy-induced anemia. Several studies recommend 150 to 300 IU/kg rHuEPO for 2 to 8 months. There are only a few controlled trials in children and no precise data about the optimal dose and duration of rHuEPO treatment is available.